🇺🇸 FDA

Intelligence · Patent portfolio

Lxo Ireland Designated Patents

Full USPTO pharma patent portfolio for Lxo Ireland Designated — grant dates, expiration, and drug cross-links.

Patents
201
Expiring ≤24m
3

Quick answer

Lxo Ireland Designated has 201 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 3 expire within 24 months — use filters for patent-cliff planning.

Page 1 of 5

  1. US 12378245

    Crystalline forms of an RSK inhibitor

    Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12297243

    Methods and compositions for reducing the immunogenicity of chimeric notch receptors

    Expires Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12291058

    Dispersions for additive manufacturing comprising discrete carbon nanotubes

    Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12268695

    Betulin-containing birch bark extracts and their formulation

    Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12247004

    2-amino-N-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use

    Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12065498

    Methods of making bispecific anti-CD307E and anti-BCMA chimeric antigen receptors and uses of the same

    Expires Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12005194

    Configurable oxygen concentrator and related method

    Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11998571

    Pharmaceutical composition comprising stem cell-conditioned medium and exosome isolated therefrom as active ingredient for prevention or treatment of ocular disease

    Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11993660

    Chimeric polypeptides and methods of altering the membrane localization of the same

    Expires Mon May 23 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11911502

    Pharmaceutical compositions and methods of using the same

    Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11883420

    Sting agonists for treating bladder cancer and solid tumors

    Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11802110

    2-amino-N-(arylsulfinyl)-acetamide compounds as inhibitors of bacterial aminoacyl-tRNA synthetase

    Expires Mon Oct 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11738015

    Pharmaceutical compositions and methods of using the same

    Expires Mon Aug 24 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11654128

    Methods and compositions for treating ectoparasite infestations

    Expires Mon May 18 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11583538

    Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors

    Expires Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11505525

    Branched discrete PEG constructs

    Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11479769

    Technique for treating cancer using structurally-reinforced S-TuD

    Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11427646

    Antibodies against carcinoembryonic antigen for cancer therapy and diagnosis

    Expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11365230

    Compositions comprising lentiviral vectors expressing IL-12 and methods of use thereof

    Expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11325957

    Methods and compositions for reducing the immunogenicity of chimeric notch receptors

    Expires Mon May 05 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11306098

    Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors

    Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11268098

    Non-aggregating immunostimulatory oligonucleotides

    Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11236055

    Non-systemic TGR5 agonists

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11161864

    Sting agonists

    Expires Mon Oct 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11135283

    Retroviral vector for the administration and expression of replicon RNA expressing heterologous nucleic acids

    Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11129805

    Dual ACE C-domain/NEP inhibitors

    Expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11111310

    Chimeric polypeptides and methods of altering the membrane localization of the same

    Expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11110106

    Sting agonists for treating bladder cancer and solid tumors

    Expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11072581

    N-acyl-arylsulfonamide derivatives as aminoacyl-tRNA synthetase inhibitors

    Expires Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11065330

    Induction of antigen-specific tolerance by peripheral phagocytosis

    Expires Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10993999

    Materials and methods for producing improved lentiviral vector particles

    Expires Mon Apr 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10993956

    GLA monotherapy for use in cancer treatment

    Expires Mon Apr 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10967346

    Microspheres and method for producing them

    Expires Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10953187

    Configurable oxygen concentrator and related method

    Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10913888

    Nanotube mediation of degradative chemicals for oil-field application

    Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10844376

    Structurally-enhanced miRNA inhibitor S-TuD

    Expires Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10828250

    Topical formulation

    Expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10758530

    Carboxamide derivatives useful as rsk inhibitors

    Expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10743542

    Preparation method and use of an atomic-state fluid iodine and its derived nano-iodine

    Expires Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10716869

    Radiolabeled macrocyclic EGFR inhibitor

    Expires Mon Jul 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10676486

    Macrocyclic RIP2 kinase inhibitors

    Expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10669242

    Clostridium difficile toxin inhibitors

    Expires Mon May 28 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10654834

    Non-systemic TGR5 agonists

    Expires Mon May 14 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10589997

    Discrete carbon nanotubes with targeted oxidation levels and stable gel formulations thereof

    Expires Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10584356

    Multigenome retroviral vector preparations and methods and systems for producing and using same

    Expires Mon Mar 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10414655

    Stem cell, bone, tissue and nerve scaffolding from discrete carbon nanotubes

    Expires Mon Sep 12 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10414656

    Discrete carbon nanotubes with targeted oxidation levels and formulations thereof

    Expires Mon Sep 12 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10406125

    Combination comprising an aminothiolester compound or a pharmaceutically acceptable salt thereof and a compound able to increase the H2O2 level in cancer cells of a subject

    Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Lxo Ireland Designated have?

201 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Lxo Ireland Designated patents expire?

3 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.